Wealthfront Advisers
ARKG icon

Wealthfront Advisers’s ARK Genomic Revolution ETF ARKG Stock Holding History

Wealthfront Advisers’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
54,659
+268
+0.5% +$8.54K ﹤0.01% 589
2026
Q1 		$1.44M Buy
54,391
+2,544
+5% +$74.5K ﹤0.01% 654
2025
Q4 		$1.5M Buy
51,847
+2,202
+4% +$66.1K ﹤0.01% 639
2025
Q3 		$1.38M Buy
49,645
+4,626
+10% +$117K ﹤0.01% 645
2025
Q2 		$1.1M Sell
45,019
-504
-1% -$11K ﹤0.01% 663
2025
Q1 		$945K Buy
45,523
+2,277
+5% +$57.2K ﹤0.01% 672
2024
Q4 		$1.02M Sell
43,246
-7
-0% -$172 ﹤0.01% 658
2024
Q3 		$1.11M Sell
43,253
-1,305
-3% -$33.2K ﹤0.01% 627
2024
Q2 		$1.05M Sell
44,558
-19,767
-31% -$499K ﹤0.01% 611
2024
Q1 		$1.85M Buy
64,325
+19,611
+44% +$590K 0.01% 498
2023
Q4 		$1.47M Buy
44,714
+4,089
+10% +$111K 0.01% 523
2023
Q3 		$1.13M Buy
40,625
+8,180
+25% +$267K ﹤0.01% 529
2023
Q2 		$1.11M Sell
32,445
-3,973
-11% -$125K ﹤0.01% 535
2023
Q1 		$1.1M Buy
36,418
+2,951
+9% +$91.4K 0.01% 510
2022
Q4 		$945K Buy
33,467
+2,453
+8% +$77.9K ﹤0.01% 522
2022
Q3 		$1.02M Sell
31,014
-2,209
-7% -$81.1K 0.01% 481
2022
Q2 		$1.05M Buy
33,223
+2,163
+7% +$75.6K 0.01% 483
2022
Q1 		$1.43M Buy
31,060
+7,783
+33% +$371K 0.01% 468
2021
Q4 		$1.43M Buy
23,277
+8,609
+59% +$595K 0.01% 447
2021
Q3 		$1.1M Buy
+14,668
New +$1.23M 0.01% 458

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wealthfront Advisers's ARKG Position: Q2 2026 in Review

Wealthfront Advisers increased its ARK Genomic Revolution ETF (ARKG) stake by 0.49% in Q2 2026, buying an estimated $8.54K and bringing the position to 54,659 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #589.

Wealthfront Advisers first reported a position in ARKG in Q3 2021 and has held it in 20 quarters since. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Wealthfront Advisers held 54,659 shares of ARK Genomic Revolution ETF worth $2.3M as of Q2 2026.
  • Wealthfront Advisers bought 268 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $8.54K.
  • ARK Genomic Revolution ETF made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #589 holding.
  • Wealthfront Advisers first reported a position in ARK Genomic Revolution ETF in Q3 2021 and has held it in 20 quarters since.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.